Barclays Has Lowered Expectations for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR) had its price objective reduced by Barclays from $69.00 to $65.00 in a report issued on Monday,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock.

A number of other equities analysts have also recently commented on BRKR. Wells Fargo & Company reduced their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Bank of America increased their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. Citigroup reduced their price objective on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. UBS Group assumed coverage on Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price on the stock. Finally, The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a research note on Thursday, December 5th. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $74.09.

Bruker Stock Performance

BRKR opened at $51.65 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The stock has a market cap of $7.83 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 3.81 and a beta of 1.16. Bruker has a 12-month low of $48.07 and a 12-month high of $94.86. The business has a 50 day moving average of $57.88 and a 200-day moving average of $60.77.

Insider Activity

In other news, CEO Frank H. Laukien acquired 100,000 shares of the stock in a transaction on Monday, November 18th. The stock was acquired at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in Bruker by 21.4% during the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after acquiring an additional 2,521,904 shares in the last quarter. Norges Bank bought a new position in Bruker in the 4th quarter valued at approximately $63,378,000. Vaughan Nelson Investment Management L.P. boosted its position in Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after buying an additional 666,617 shares in the last quarter. Point72 DIFC Ltd grew its stake in shares of Bruker by 4,875.9% during the third quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company’s stock worth $32,470,000 after buying an additional 460,722 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Bruker by 1,933.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock worth $28,331,000 after buying an additional 390,057 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.